HF/CM risks in breast chemotherapy
Earlier study findings that anthracycline- or trastuzumab-based treatment for breast cancer raises the risk for heart failure and cardiomyopathy can be extended to a more general population of women.
Diagnosis & Disease Information
Heart drugs turn cancer cells into anticancer vaccines
Plant-based drugs primarily used in the treatment of heart failure and arrhythmias have now been found to exert anticancer effects.
Persistent headache plagues an immunocompromised patient
Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient’s unexplained neurologic symptoms.
Kidney transplant drug boosts immune activity in breast cancer
Daclizumab, which prevents organ rejection after renal transplant, improved survival in persons with breast cancer receiving a therapeutic vaccine.
Breast cancer vaccine works better with letrozole than with tamoxifen
A vaccine significantly increased survival in mice with breast cancer when given with the hormonal therapy letrozole, but not with tamoxifen.
Survival improves for youths with leukemia
The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia rose from 83.7% for 1990-1994 to 90.4% for 2000-2005.
Abscopal effect strengthens combination therapy in a melanoma patient
Combination therapy may be a promising treatment approach for patients with advanced melanoma who experience the abscopal effect.
New drugs change treatment landscape for advanced prostate cancer
Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.
Vaccine used in early breast cancer shows good immunity response
Many women with early breast cancer experienced a sustained immune response after immunization with a vaccine that fights HER2, and this may reduce their risk for more invasive cancer.
Therapeutic vaccine for brain cancer being studied
A vaccine for people newly diagnosed with glioblastoma multiforme—the most aggressive and highest-grade malignant glioma—is being tested at 20 sites nationwide in a phase II trial.
- Loading...
Loading...
Loading... 
Loading...